Scherak O, Smolen JS, Menzel EJ, Kojer M, Kolarz G. Effect of levamisole on immunological parameters in patients with systemic lupus erythematosus.
Scand J Rheumatol 1980;
9:106-12. [PMID:
6968971 DOI:
10.3109/03009748009098138]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Parameters of cell-mediated and humoral immunity were examined in 8 patients with clinically inactive SLE undergoing levamisole treatment. Lymphocyte transformation with PHA and PMW was temporarily increased in the first month of therapy; at the same time absolute numbers of peripheral blood lymphocytes, T cells and B cells increased slightly. However, these differences were not significant statistically. In 1 patient with a diminished percentage of T cells and an increased percentage of B cells, levamisole induced normalization. Antibodies to DNA decreased in 6 patients, while titres of ANA decreased only in one patient. Serum levels of C1q and C3 increased in 7 and 3 patients, respectively. Four patients were treated with levamisole for 12 months, during which time there was neither clinical exacerbation nor deterioration of renal function and the concomitant corticosteroid therapy could be reduced.
Collapse